PharmaCyte Biotech IncPMCB
Price$0.40

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Jul 2026
Net Income -$19.4M-163.4% YoYTTM through 31 Jul 2026
Free Cash Flow -$3.9MTTM through 31 Jul 2026

Margins

Current

Returns

2.0%ROE
1.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio12.33x
Net Debt-$20.5Mnet cash position
Cash & Equivalents$17.7M

Quality Metrics

Altman Z-Score-3.38
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25'26
FY2026: $0
Diluted EPS-$2.08TTM
'20'21'22'23'24'25'26
FY2026: $-2.32

Dividend

No dividend

Capital Allocation

R&D Spend$356.1K

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.